VYGR
Voyager Therapeutics, Inc.
Key Financials
Net Income
$-119721000
↓ 84.2%
Operating Income
$-131844000
↓ 58.3%
Revenue
$40.4M
↓ 49.5%
Total Liabilities
$56.2M
↓ 39.8%
Total Assets
$252.3M
↓ 35.8%
EPS (Diluted)
$-2.04
↓ 80.5%
Shareholders' Equity
$196.1M
↓ 34.6%
Cash & Equivalents
$65.3M
↓ 8.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 8-K | 8/6/2026 | View on SEC |
| 10-Q | 8/6/2026 | View on SEC |
| SCHEDULE 13G/A | 7/31/2026 | View on SEC |
| 8-K | 7/13/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | VYGR |
| Company Name | Voyager Therapeutics, Inc. |
| CIK | 1640266 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 857-259-5340 |